Sequel Med Tech today announced clinical findings supporting its twiist automated insulin delivery (AID) system in type 2 diabetes. twiist, which works with the twiist Loop algorithm, powered by Tidepool, directly measures the volume of insulin delivered with every microdose. The system offers the capability and flexibility to address each patient’s individual dosing needs. Sequel’s system […]
Diabetes
Adaptyx study backs wearable multi-analyte sensor
Adaptyx Biosciences today announced clinical findings supporting its wearable sensor for continuous, multi-day free cortisol measurement. Menlo Park, California-based Adaptyx, a Stanford University spinout, shared the first data for its sensor at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. The studies looked at the sensor measuring free cortisol from dermal interstitial […]
Senseonics study supports Eversense 365 CGM with automated insulin delivery tech
Senseonics (NYSE:SENS) today announced real-world evidence supporting the performance of its Eversense 365 year-long CGM implant. Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. Germantown, Maryland-based Senseonics said data […]
Dexcom study highlights benefits of G7 CGM in non-insulin type 2 diabetes
Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 diabetes. The CONNECT study evaluated the current-generation G7 continuous glucose monitor (CGM) in people with type 2 diabetes not using insulin. It compared this population to a routine care control group using self-monitoring of blood glucose. Researchers shared […]
Abbott studies reinforce DKA opportunity following dual sensor milestone
Abbott (NYSE:ABT) today announced new clinical data highlighting the importance of managing diabetic ketoacidosis (DKA). The medtech giant shared findings from multiple studies at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans that demonstrate sharp increases in DKA-related hospitalizations across all age groups with type 1 and type 2 diabetes nationwide. Abbott […]
Insulet data backs Omnipod 6, fully closed-loop AID systems
Insulet (Nasdaq:PODD) today announced new clinical findings for its next-generation Omnipod 6 and fully closed-loop algorithm. The company shared results from its STRIVE pivotal trial and EVOLUTION 3 feasibility study. Investigators presented the outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Findings demonstrated meaningful improvements in glucose control for people […]
Tidepool data highlights automated insulin delivery algorithm enhancements, women’s health initiative
Tidepool has new clinical insights and research initiatives related to diabetes management and automated insulin delivery (AID) technology. Palo Alto, California-based Tidepool is a non-profit diabetes data management group. It developed the FDA-cleared Tidepool Loop, a “do-it-yourself” (DIY) AID system. The hybrid, closed-loop AID app has compatibility with multiple insulin pumps and continuous glucose monitors. […]
MannKind shares more data backing inhaled insulin
MannKind (Nasdaq:MNKD) today announced new clinical findings for its Afrezza inhaled insulin powder and Furoscix furosemide injection. The company shared outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. MannKind’s Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to […]
Glooko launches EHR integration for insulin pumps
Glooko announced today that it launched its Insulin Pump Settings Electronic Health Record (EHR) integration capability. Palo Alto, California-based Glooko says the first-of-its-kind capability within its latest software release visualizes critical insulin pump configuration data directly into the clinical workflow. The company says that visibility of pump settings provides essential clinical context for clinics caring […]
Tandem wins CE mark for automated insulin delivery in type 2 diabetes, pregnancy
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received expanded CE mark for its automated insulin delivery (AID) systems. San Diego-based Tandem can now bring its Control-IQ-powered AID systems — the flagship t:slim X2 and miniature Mobi — to European adults with type 2 diabetes and those with type 1 diabetes during pregnancy. Approval in […]
